Novel treatment and prevention of aphthous stomatitis
| Reference number | |
| Coordinator | Mucocort AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | June 2019 - March 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups stage 2 - spring 2019 |
Important results from the project
** Denna text är maskinöversatt ** The most common oral mucosal problem in the population is cold sores called recurrent aphthous stomatitis (RAS). About 20% of all people have annual recurrences and there are several products on the market, but few have a documented effect. The current projectgoal is to develop a new mucoadhesive patch formulation for recurrent RAS with good effects. The patch that we are developing, should be able to provide a instant rapid pain relief and also promote natural healing in children as well as adults.
Expected long term effects
We have now developed a patch with the properties we sought. We have now started biocompability study and also started a collaboration with a Swedish contract manufacturer. We are also working with a potential packaging with interesting properties that affect the environment less. We have also signed an agreement for a study at a Swedish hospital which is expected to start in August / September 2021.
Approach and implementation
We are working on registering our patch according to ISO13485 for an CE-MDR 2A certification. Our studies are conducted in accordance with ISO10993 and ISO14155. Our company is part of incubators for UBI in Umeå. We also strive for those we work with to be published. The ambition for our activities is to treat patients with a sustainable solution with the least impact on nature.